Determining the stability of silver nanoparticles is a very important process. It was associated with unwanted metal charge and materials properties. Therefore, we studied to synthesis and stability of silver nanoparticles (AgNPs). The synthesis was performed by reduction method used sodium borohydride (NaBH 4). Silver nitrate solution 0.0005 M in 1 mL was reduced using 1 mL 0.002 M of NaBH 4. Then a 40.0 L of polyvinylpyrrolidone 0.3% and 20 L of 1.5 N NaCl was added to the mixture. Characterization of silver nanoparticles is undertaken using spectrophotometer UV-Vis, transmission electron microscopy, particle size analyzer and zeta potential. The stability of products is observed for 5 times using spectrophotometer UV-Vis. The product was characterized by determining its surface plasmon resonance (SPR) of AgNPs and the result was obtained at 403 nm. The size of AgNPs was 20 nm using tomography emission microscopy analysis and the particle size distribution give 5.8 nm. The dielectric charge was 53 mV. The stable AgNPs showed no significant SPR shift at 402±0.89 nm wavelength during 5 days observation. Based on the size and stability, it was suitable for imaging materials.
ABSTRAK KARAKTERISTIK PEMISAHAN RADIOLUTESIUM- 177/177mLu DAN RADIOITERBIUM-169/175Yb PADA KOLOM RESIN LN-EICHROM. Radiolutesium-177Lu keradioaktifan jenis tinggi merupakan salah satu radiolantanida yang banyak digunakan untuk menangani berbagai kasus kanker, namun di Indonesia penggunaan radiofarmaka bertanda 177Lu belum dapat dijanjikan karena teknik produksi radioisotop primernya belum dikuasai. Prospek produksi 177Lu melalui reaksi inti 176Yb (n,g) 177Yb* à 177Lu* + β– dipelajari melalui metode pemisahan matrik 177/177mLu-169/175Yb/176Yb dalam sistem kromatografi kolom resin LN-Eichrom. Profil fraksinasi dan karakteristik pemisahan dipelajari dengan pemeriksaan keradioaktifan dan analisis spektro-metri-g terhadap hasil elusi larutan sasaran pasca iradiasi. Bahan sasaran digunakan 176Yb2O3 alam dan 176Lu2O3 diperkaya. Hasil penelitian menunjukkan bahwa radiolutesium-177/177mLu dapat dipisahkan dari matrik radioiterbium-169/175Yb/natYb melalui sistem kromatografi kolom dengan fase diam resin LN-Eichrom dan fase gerak larutan HNO3, dengan konsentrasi antara 1,5 – 4 M untuk mendapatkan pemisahan yang efektif, selektif dan kuantitatif. Reaksi inti 176Yb(n,g) 177Yb* à 177Lu + β– merupakan model reaksi inti yang perlu dipertimbangkan walau-pun harus melibatkan tahapan pemisahan produk 177Lu dari matrik sasaran Yb pasca iradiasi. Prosedur pemisahan yang dilakukan masih perlu diperbaiki melalui pemilihan jenis dan konsentrasi fase gerak pengelusi yang lebih tepat. ABSTRACT SEPARATION CHARACTERISTIC OF RADIOLUTETIUM-177/177mLu AND RADIOY-TTERBIUM-169/175Yb ON LN-EICHROM RESIN COLUMN. High specific activity radiolutetium-177Lu is one of radiolanthanides that is widely used to handle variety of cancer cases, but in Indonesia the use of 177Lu-labeled-radiopharmaceutical can not be promised yet as the primary radioisotope production techniques have not been mastered. The prospect of 177Lu production based on the nuclear reaction of 176Yb (n,g) 177Yb * ® 177Lu * + β– in the BATAN’s G.A. Siwabessy reactor was learned through the separation characteristics of 177/177mLu-169/175Yb /176Yb process matrices in the LN-Eichrom resin column chromatography. The separation and fractionation profiles were characterized by radioactivity measurement as well as g-spectrometric analysis of the eluting post-irradiated target solution. The target materials used were natural 176Yb2O3 and enriched 176Lu2O3. The results showed that radiolutetium-177/177mLu can be separated from the radioiterbium-169/175Yb/natYb matrix by column chromatography system with a stationary phase of LN-Eichrom resin using HNO3 solution as the mobile phase, but the concentration of HNO3 used is a critical variable, between 1.5 - 4 M, to obtain an effective separation selectively and quantitatively. The nuclear reaction of 176Yb (n,g) 177Yb* ® 177Lu + β– using natural Yb2O3 is considered to be better, although it must involve 177Lu product separation stage from the post-irradiated natural Yb target matrix. The presented separation procedure still needs to be improved through the selection of the type and the concentration of the mobile phase used to gain more appropriate elution solvent.
Radiotherapy is an effective cancer therapy, where a certain dose of radiation is aimed specifically at target and is unaffecting to normal tissue. A selective radionuclide must be attached to the specific targeted organ. In this research, silver nanoparticles (AgNPs) were labeled with radionuclide of iodine-131 (131 I) to be used in radiotherapy. Silver nanoparticles were synthesized using silver nitrate 0.0005 M, sodium borohydride 0.002 M, polyvinylpyrrolidone 0.3 % (w/v) and natrium chloride 1.5 M, and then followed by purification by centrifugation. Characterization was carried out with UV-Vis spectrophotometer, transmission electron microscope, particle size analyzer, and zeta-sizer. The results show that the maximum absorbance is on a wavelength of 398 nm, spherical shape with a diameter of 10 nm, polydispersity index of 0.455, and zeta potential value of-8 mV. The radiolabeling was done by adding sodium iodide-131 which had been oxidized by chloramine-T and immobilized in AgNPs colloidal solution, and the activity was then measured using a dose calibrator. The identification of radionuclide showed that the sample was free of impurities. The optimum system of radiochemical purity was obtained using Whatman 1 paper strip as the stationary phase and a mixture of methanol: water: ammonium acetate (1:1:1) as the mobile phase, which gave 96 % purity. This method is suitable for radiolabeling AgNPs with 131 I to be used for radiotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.